Drug Profile


Alternative Names: DS 4823; SD 3211; Sesamodil

Latest Information Update: 03 Jan 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Daiichi Pharmaceutical; Santen Pharmaceutical
  • Class Antihypertensives; Ischaemic heart disorder therapies
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris; Arrhythmias; Hypertension

Most Recent Events

  • 03 Jan 2001 Discontinued-II for Angina pectoris in Europe (PO)
  • 03 Jan 2001 Discontinued-II for Arrhythmias in Japan (PO)
  • 03 Jan 2001 Discontinued-II for Hypertension in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top